Phase I Trial of Low-Dose Cyclophosphamide in Combination With Veliparib (ABT-888) in HER2/Neu-Negative Metastatic Breast Cancer
Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 14 Dec 2017
At a glance
- Drugs Cyclophosphamide (Primary) ; Veliparib (Primary)
- Indications Advanced breast cancer
- Focus Adverse reactions
- 10 Jun 2017 Biomarkers information updated
- 21 Jul 2016 Planned primary completion date changed from 1 May 2017 to 1 Nov 2016.
- 21 Jul 2016 Status changed from recruiting to active, no longer recruiting.